Owing to imatinib resistance and favorable prognosis, patients with GIST bearing PDGFRA D842V substitutions are not generally considered to be candidates for adjuvant imatinib therapy [44, 45]. The gene discussed is PDGFRA; the disease is gastrointestinal stromal tumor.